Allecra Therapeutics GmbH

Allecra Therapeutics GmbH

Allecra Therapeutics GmbH

Overview
Date Founded

2013

Headquarters

Im Kränzliacker 9,Weil am Rhein, Baden Wuerttemberg 79576

Type of Company

Private

Employees (Worldwide)

1 - 10

Industries

Pharmaceuticals
Biotechnology
Holding Companies

Company Description

Allecra Therapeutics GmbH focuses on the development of novel treatments to combat multi drug-resistant bacterial infections. The firm serves the bio and pharmaceutical industry. The company was founded by Nicholas Benedict and Stuart Shapiro in 2013 and is headquartered in Weil am Rhein, Germany.

Executives & Employees

Chief Executive Officer & Managing Director

Chief Financial Officer

Chief Development Officer

Interim Chief Medical Officer

Head of Chemistry, Manufacturing & Controls

Managing Director & Chief Development Officer

Director of Regulatory Affairs

Board of Directors

General Partner at Forbion Capital Partners Management Holding BV

Director, Chief Executive & Financial Officer at Tanvex Biopharma, Inc.

Paths to Allecra Therapeutics GmbH
Potential Connections via
Relationship Science
You
Allecra Therapeutics GmbH
Investors
Details Hidden

Xeraya Capital invests in life science companies located across the Globe. The Firm focuses on companies operating in the fields of medical technologies, pharmaceutical biotech and bio-renewables. They provide financing for early stage capital requirements and also takes minority equity positions. It also co-manages Mudharabah Innovation Fund.

Details Hidden

BMP is a venture capital investment manager providing private equity and mezzanine financing to healthcare and human life science companies. The firm focuses on startups, young businesses and spinoffs in the biotechnology, emerging pharmaceuticals, medical technology and diagnostics sectors. They invest in Switzerland and neighboring countries.BioMedInvest is a venture capital fund invested in direct equity. BMP actively scouts for investment opportunities through their network of academic contacts. They target businesses with exceptional growth potential which are driven by distinctive technologies or offering services with unique advantages over current treatments. They generally participate in the first round of financing, either as the lead investor or through syndication with private equity firms and private individuals. The firm fosters the growth of their portfolio companies through management consulting and business support services. Their exit strategies include IPO and sale to leading pharmaceutical corporations or to strategic investors.BioMedInvest II LP is a venture capital fund focused on healthcare-related investments. The fund supports early-stage private firms as well as spin-offs active in segments such as emerging pharmaceutical, biotechnology, medical technology, diagnostics or platform technologies. They look for investments primarily in Switzerland, Germany and neighboring Western Europe. The fund typically invests in a range from CHF 1 million to CHF 10 million, as lead or co-lead investor.BioMedCredit is a mezzanine fund providing growth and expansion capital to small- and mid-size innovative businesses in Switzerland offering specialized services which may not have significant scaling-up potential. They focus on firms operating in products, technologies and services, specifically in the fields of biotechnology, emerging pharmaceuticals, analytical services, biomaterials, bioengineering, bioinformatics, down-stream processing, biotechnological platform technologies, chemical products and reagents, contract R&D and manufacturing, diagnostics, drug delivery technologies, lab technologies, automation, cell culture technologies as well as medical technology. The amount invested of the portfolio firms' lifetime ranges from CHF 0.5 million to CHF 5 million.

Details Hidden

Delos Advisors (Delos Capital Partners/Delos Life Sciences) invests in companies located in Greater China and US. The firm invests in health care therapeutics and medical technology companies. They provides financing in the form of later stage capital, buyout, direct or indirect private equity investments, restructuring, recapitalizations, strategic investments and growth stage capital and also makes investments in public listed companies.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Allecra Therapeutics GmbH. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Allecra Therapeutics GmbH's profile does not indicate a business or promotional relationship of any kind between RelSci and Allecra Therapeutics GmbH.